Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023

血漿分画製剤の世界市場予測(~2023年):商品別(IVIG(静注免疫グロブリン)、アルブミン、第VIII因子、フォンヴィレブラント因子、PCC (プロトロンビン複合体製剤)、プロテアーゼ阻害剤)、用途別(免疫療法、血液疾患、救命治療、リウマチ)、エンドユーザー別(病院、クリニック、学術研究機関)

◆タイトル:Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023
◆商品コード:MAM-PH-4477
◆調査・発行会社:MarketsandMarkets
◆発行日:2018年2月1日
◆ページ数:249
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥632,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥744,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥912,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、血漿分画製剤の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、種類別分析、セグメント別分析、地域別分析、血漿分画製剤の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業インサイト
・血漿分画製剤市場:商品別
・血漿分画製剤市場:用途別
・血漿分画製剤市場:エンドユーザー別
・地域別分析
・競争状況
・企業プロファイル
・付録

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.

The protease inhibitors segment is expected to grow at the highest CAGR during the forecast period
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.

The pulmonology segment is projected to witness the highest growth during the forecast period
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment
is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.

The hospitals and clinics segment is expected to grow at the highest CAGR during the forecast period
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.

Asia Pacific to witness the highest growth during the forecast period
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region’s large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–46%, Tier 2–33% and Tier 3–21%
• By Designation – C Level–43%, Director Level–35%, Others–22%
• By Region – North America–34%, Europe–26%, Asia Pacific–24%, Latin America–12%, Middle East and Africa- 4%
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Research Coverage:
The report analyzes the plasma fractionation market and aims at estimating the market size and future growth potential of this market based on various segments such as product, application, end user, and region. The report also includes a volume data analysis for various plasma products across the globe and a competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global plasma fractionation market. The report analyzes the global plasma fractionation market by product, application, end user, and region.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global plasma fractionation market.
• Market Development: Comprehensive information on the lucrative emerging markets by product, application, end user, and region.
• Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the global plasma fractionation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of leading players in the global plasma fractionation market.

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 SCOPE OF THE STUDY 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY SOURCES 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY SOURCES 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.2.1 BOTTOM-UP APPROACH 26
2.2.2 TOP-DOWN APPROACH 27
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.4 MARKET SHARE ESTIMATION 29
2.5 ASSUMPTIONS FOR THE STUDY 29
2.6 LIMITATIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 34
4.2 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018 35
4.3 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET 36
4.4 PLASMA FRACTIONATION MARKET: REGIONAL MIX 37
4.5 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS.
DEVELOPED COUNTRIES 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 MARKET DRIVERS 39
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 39
5.2.1.2 Rising geriatric population across the globe 40
5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin 41
5.2.1.4 Increase in plasma collection 42
5.2.2 MARKET RESTRAINTS 44
5.2.2.1 High cost and limited reimbursement 44
5.2.2.2 Emergence of recombinant alternatives 44
5.2.3 MARKET OPPORTUNITY 45
5.2.3.1 Increasing number of hemophilia patients 45
5.2.4 MARKET CHALLENGE 46
5.2.4.1 Stringent government regulations 46
6 INDUSTRY INSIGHTS 48
6.1 INTRODUCTION 48
6.2 KEY INDUSTRY TRENDS 49
6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES AND GEOGRAPHICAL EXPANSIONS 50
6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS 51
6.2.3 RISING ADOPTION OF SCIG 51
6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 52
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 53
6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS 55
6.3 PORTER’S FIVE FORCES 57
6.3.1 THREAT FROM NEW ENTRANTS 57
6.3.2 THREAT OF SUBSTITUTES 58
6.3.3 BARGAINING POWER OF SUPPLIERS 58
6.3.4 BARGAINING POWER OF BUYERS 59
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 59
6.4 VENDOR BENCHMARKING 60

7 PLASMA FRACTIONATION MARKET, BY PRODUCT 62
7.1 INTRODUCTION 63
7.2 IMMUNOGLOBULIN 64
7.2.1 INTRAVENOUS IMMUNOGLOBULIN (IVIG) 66
7.2.2 SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) 70
7.2.3 OTHER IMMUNOGLOBULINS 72
7.3 COAGULATION FACTOR CONCENTRATES 75
7.3.1 FACTOR VIII 77
7.3.2 FACTOR IX 80
7.3.3 VON WILLEBRAND FACTOR 83
7.3.4 PROTHROMBIN COMPLEX CONCENTRATE 84
7.3.5 FIBRINOGEN CONCENTRATES 86
7.3.6 FACTOR XIII 87
7.4 ALBUMIN 89
7.5 PROTEASE INHIBITORS 92
7.6 OTHER PLASMA PRODUCTS 94
8 PLASMA FRACTIONATION MARKET, BY APPLICATION 95
8.1 INTRODUCTION 96
8.2 NEUROLOGY 97
8.3 IMMUNOLOGY 99
8.4 HEMATOLOGY 101
8.5 CRITICAL CARE 104
8.6 PULMONOLOGY 105
8.7 HEMATO-ONCOLOGY 107
8.8 RHEUMATOLOGY 108
8.9 OTHER APPLICATIONS 110
9 PLASMA FRACTIONATION MARKET, BY END USER 112
9.1 INTRODUCTION 113
9.2 HOSPITALS & CLINICS 114
9.3 CLINICAL RESEARCH LABORATORIES 115
9.4 ACADEMIC INSTITUTES 117
10 GEOGRAPHIC ANALYSIS 119
10.1 INTRODUCTION 120
10.2 NORTH AMERICA 122
10.2.1 US 127
10.2.2 CANADA 132

10.3 EUROPE 135
10.3.1 GERMANY 141
10.3.2 FRANCE 145
10.3.3 ITALY 148
10.3.4 SPAIN 152
10.3.5 UK 155
10.3.6 REST OF EUROPE 159
10.4 ASIA PACIFIC 163
10.4.1 CHINA 167
10.4.2 JAPAN 170
10.4.3 INDIA 174
10.4.4 MALAYSIA 177
10.4.5 REST OF ASIA PACIFIC 181
10.5 LATIN AMERICA 184
10.6 MIDDLE EAST & AFRICA 187
11 COMPETITIVE LANDSCAPE 191
11.1 OVERVIEW 191
11.2 MARKET SHARE ANALYSIS 192
11.3 COMPETITIVE SCENARIO AND TRENDS 194
11.3.1 EXPANSIONS 194
11.3.2 PRODUCT LAUNCHES 195
11.3.3 ACQUISITIONS 195
11.3.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS 196
12 COMPANY PROFILES 197
(Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*
12.1 CSL 197
12.2 GRIFOLS 201
12.3 SHIRE 205
12.4 OCTAPHARMA 209
12.5 KEDRION 211
12.6 LFB 215
12.7 BIOTEST 218
12.8 SANQUIN 221
12.9 CHINA BIOLOGIC PRODUCTS 223
12.10 BIO PRODUCTS LABORATORY (BPL) 226

12.11 JAPAN BLOOD PRODUCTS ORGANIZATION 228
12.12 GREEN CROSS CORPORATION 231
12.13 SHANGHAI RAAS BLOOD PRODUCTS 234
*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 236
13.1 INSIGHTS OF INDUSTRY EXPERTS 236
13.2 DISCUSSION GUIDE 237
13.3 AVAILABLE CUSTOMIZATION 241
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 244
13.6 RELATED REPORT 246
13.7 AUTHOR DETAILS 247

LIST OF TABLES

TABLE 1 PLASMA FRACTIONATION MARKET: IMPACT ANALYSIS 38
TABLE 2 ON-LABEL AND OFF-LABEL INDICATIONS OF IVIG 39
TABLE 3 NUMBER OF CLINICAL STUDIES ON IMMUNOGLOBULINS, BY REGION, 2017 40
TABLE 4 INCREASE IN GERIATRIC POPULATION FROM 2000 TO 2050 ACROSS THE GLOBE 40
TABLE 5 NUMBER OF PLASMA COLLECTION CENTERS (2017) 43
TABLE 6 NUMBER OF HEMOPHILIA PATIENTS IN DEVELOPED AND EMERGING
COUNTRIES, 2016 45
TABLE 7 CHARACTERISTICS OF PLASMA FOR FRACTIONATION 46
TABLE 8 FRACTIONATION CAPACITY EXPANSIONS BY MAJOR PLAYER 50
TABLE 9 PER CAPITA CONSUMPTION OF IVIG AND ALBUMIN, BY COUNTRY (2014) 54
TABLE 10 CHINA:TOP PLAYERS IN ALBUMIN MARKET, 2017 54
TABLE 11 MAJOR LOCAL PLAYERS IN CHINA 55
TABLE 12 REGIONAL IMPACT ANALYSIS OF RECOMBINANT FACTORS ON PLASMA-DERIVED PRODUCTS 56
TABLE 13 PRODUCT PORTFOLIO ANALYSIS: PLASMA FRACTIONATION MARKET 60
TABLE 14 PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 63
TABLE 15 IMMUNOGLOBULIN MARKET, BY TYPE, 2016–2023 (USD MILLION) 64
TABLE 16 IMMUNOGLOBULIN MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 65
TABLE 17 GLOBAL IMMUNOGLOBULIN MARKET, BY REGION, 2016–2023 (METRIC TONS) 65
TABLE 18 INTRAVENOUS IMMUNOGLOBULIN OFFERED BY KEY MARKET PLAYERS 68
TABLE 19 IVIG MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 69
TABLE 20 IVIG MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 69
TABLE 21 COMPARISON OF PROS AND CONS, IVIG VS SCIG THERAPY 70
TABLE 22 SCIG OFFERED BY KEY MARKET PLAYERS 71
TABLE 23 SCIG MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 71
TABLE 24 OTHER IMMUNOGLOBULINS OFFERED BY KEY MARKET PLAYERS 72
TABLE 25 OTHER IMMUNOGLOBULINS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 74
TABLE 26 COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 76
TABLE 27 COAGULATION FACTOR CONCENTRATES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 76
TABLE 28 FACTOR VIII OFFERED BY KEY MARKET PLAYERS 78
TABLE 29 GLOBAL FACTOR VIII MARKET, BY REGION,
2016–2023 (MILLION INTERNATIONAL UNITS) 79
TABLE 30 FACTOR VIII MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 79
TABLE 31 FACTOR VIII MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 80
TABLE 32 FACTOR IX OFFERED BY KEY MARKET PLAYERS 81
TABLE 33 FACTOR IX MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 82
TABLE 34 VON WILLEBRAND FACTOR OFFERED BY KEY MARKET PLAYERS 83
TABLE 35 VON WILLEBRAND FACTOR MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 84
TABLE 36 PROTHROMBIN COMPLEX CONCENTRATE OFFERED BY KEY MARKET PLAYERS 85
TABLE 37 PROTHROMBIN COMPLEX CONCENTRATE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 85
TABLE 38 FIBRINOGEN CONCENTRATES OFFERED BY KEY MARKET PLAYERS 86
TABLE 39 FIBRINOGEN CONCENTRATES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 87
TABLE 40 FACTOR XIII OFFERED BY KEY MARKET PLAYERS 88
TABLE 41 FACTOR XIII MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 88
TABLE 42 ALBUMIN OFFERED BY KEY MARKET PLAYERS 89
TABLE 43 ALBUMIN MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 90
TABLE 44 GLOBAL ALBUMIN MARKET, BY REGION, 2016–2023 (METRIC TONS) 91
TABLE 45 PROTEASE INHIBITORS OFFERED BY KEY MARKET PLAYERS 92
TABLE 46 PROTEASE INHIBITORS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 93
TABLE 47 OTHER PLASMA PRODUCTS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 94
TABLE 48 PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 96
TABLE 49 NUMBER OF DALYS FOR NEUROLOGICAL DISORDERS AND A PERCENTAGE OF DALYS PROJECTED FOR 2005, 2015, AND 2030 97
TABLE 50 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN NEUROLOGY 98
TABLE 51 PLASMA FRACTIONATION MARKET FOR NEUROLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 98
TABLE 52 LIST OF FDA APPROVED INDICATIONS FOR IMMUNOGLOBULINS IN IMMUNOLOGY 99
TABLE 53 PREVALENCE OF PID, BY REGION, 2013 VS. 2015 100
TABLE 54 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN IMMUNOLOGY 100
TABLE 55 PLASMA FRACTIONATION MARKET FOR IMMUNOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 101
TABLE 56 NUMBER OF HEMOPHILIC PATIENTS (2012–2016) 101
TABLE 57 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN HEMATOLOGY 103
TABLE 58 PLASMA FRACTIONATION MARKET FOR HEMATOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 103
TABLE 59 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN CRITICAL CARE 104
TABLE 60 PLASMA FRACTIONATION MARKET FOR CRITICAL CARE, BY COUNTRY,
2016–2023 (USD MILLION) 105
TABLE 61 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN PULMONOLOGY 106
TABLE 62 PLASMA FRACTIONATION MARKET FOR PULMONOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 106
TABLE 63 ESTIMATED CANCER INCIDENCE, BY REGION, 2012 VS. 2015 107
TABLE 64 PLASMA-DERIVED PRODUCTS AND ITS APPLICATIONS IN HEMATO-ONCOLOGY 107
TABLE 65 PLASMA FRACTIONATION MARKET FOR HEMATO-ONCOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 108
TABLE 66 PLASMA FRACTIONATION MARKET FOR RHEUMATOLOGY, BY COUNTRY,
2016–2023 (USD MILLION) 109
TABLE 67 PLASMA-DERIVED PRODUCTS AND ITS OTHER APPLICATIONS 110
TABLE 68 PLASMA FRACTIONATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016–2023 (USD MILLION) 111
TABLE 69 PLASMA FRACTIONATION MARKET, BY END USER, 2016–2023 (USD MILLION) 113
TABLE 70 PLASMA FRACTIONATION MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2016–2023 (USD MILLION) 115
TABLE 71 CLINICAL STUDIES ON ALBUMIN & IMMUNOGLOBULIN (2017) 116
TABLE 72 PLASMA FRACTIONATION MARKET FOR CLINICAL RESEARCH LABORATORIES,
BY COUNTRY, 2016–2023 (USD MILLION) 116
TABLE 73 PLASMA FRACTIONATION MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2016–2023 (USD MILLION) 118
TABLE 74 NUMBER OF PLASMA FRACTIONATION PLANTS, BY REGION, 2014 120
TABLE 75 PLASMA FRACTIONATION MARKET, BY REGION, 2016–2023 (USD MILLION) 121
TABLE 76 NORTH AMERICA: HEMOPHILIA PATIENTS, 2013 VS. 2016 122
TABLE 77 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 124
TABLE 78 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 124
TABLE 79 NORTH AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2016–2023 (USD MILLION) 124
TABLE 80 NORTH AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 81 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 125
TABLE 82 NORTH AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 126
TABLE 83 US: NUMBER OF PLASMA DONATIONS & PLASMA DONATION CENTERS 127
TABLE 84 US: KEY MACROINDICATORS 129
TABLE 85 US: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 129
TABLE 86 US: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 87 US: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 130
TABLE 88 US: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 130
TABLE 89 US: PLASMA FRACTIONATION MARKET, BY END USER, 2016–2023 (USD MILLION) 131
TABLE 90 CANADA: KEY MACROINDICATORS 133
TABLE 91 CANADA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 133
TABLE 92 CANADA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 93 CANADA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 134
TABLE 94 CANADA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 134
TABLE 95 CANADA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 135
TABLE 96 EUROPE: NUMBER OF PLASMA DONATION CENTERS 135
TABLE 97 PLASMA FRACTIONATION PLANTS IN EUROPE (2017) 136
TABLE 98 EUROPE: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 138
TABLE 99 EUROPE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 138
TABLE 100 EUROPE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 101 EUROPE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 139
TABLE 102 EUROPE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 139
TABLE 103 EUROPE: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 140
TABLE 104 GERMANY: KEY MACROINDICATORS 142
TABLE 105 GERMANY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 142
TABLE 106 GERMANY: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 143
TABLE 107 GERMANY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 143
TABLE 108 GERMANY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 144
TABLE 109 GERMANY: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 144
TABLE 110 NUMBER OF PEOPLE WITH BLEEDING DISORDERS IN FRANCE: 2012–2016 145
TABLE 111 FRANCE: KEY MACROINDICATORS 146
TABLE 112 FRANCE: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 146
TABLE 113 FRANCE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 114 FRANCE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 147
TABLE 115 FRANCE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 147
TABLE 116 FRANCE: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 148
TABLE 117 ITALY: NUMBER OF BLOOD DONATIONS, 2011 VS. 2013 148
TABLE 118 PRODUCTION OF PLASMA PRODUCTS IN ITALY (2013) 149
TABLE 119 ITALY: KEY MACROINDICATORS 150
TABLE 120 ITALY: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 150
TABLE 121 ITALY: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 150
TABLE 122 ITALY: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 151
TABLE 123 ITALY: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 151
TABLE 124 ITALY: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 152
TABLE 125 SPAIN: KEY MACROINDICATORS 153
TABLE 126 SPAIN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 153
TABLE 127 SPAIN: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 153
TABLE 128 SPAIN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 154
TABLE 129 SPAIN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 154
TABLE 130 SPAIN: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 155
TABLE 131 USAGE OF IMMUNOGLOBULINS 155
TABLE 132 ESTIMATED NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS IN THE UK, 2012–2016 156
TABLE 133 UK: KEY MACROINDICATORS 157
TABLE 134 UK: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 157
TABLE 135 UK: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 157
TABLE 136 UK: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 158
TABLE 137 UK: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 158
TABLE 138 UK: PLASMA FRACTIONATION MARKET, BY END USER, 2016–2023 (USD MILLION) 159
TABLE 139 TOTAL NUMBER OF HEMOPHILIA PATIENTS IN THE ROE: 2012–2016 160
TABLE 140 ROE: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 160
TABLE 141 ROE: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 161
TABLE 142 ROE: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 161
TABLE 143 ROE: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 162
TABLE 144 ROE: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 162
TABLE 145 APAC: PLASMA FRACTIONATION MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 165
TABLE 146 APAC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 165
TABLE 147 APAC: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 165
TABLE 148 APAC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 166
TABLE 149 APAC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 166
TABLE 150 APAC: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 167
TABLE 151 CHINA: KEY MACROINDICATORS 168
TABLE 152 CHINA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 169
TABLE 153 CHINA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 169
TABLE 154 CHINA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 155 CHINA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 170
TABLE 156 CHINA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 170
TABLE 157 JAPAN: KEY MACROINDICATORS 171
TABLE 158 JAPAN: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 171
TABLE 159 JAPAN: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 172
TABLE 160 JAPAN: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 172
TABLE 161 JAPAN: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 173
TABLE 162 JAPAN: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 173
TABLE 163 INDIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS: 2012–2016 174
TABLE 164 INDIA: KEY MACROINDICATORS 175
TABLE 165 INDIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 175
TABLE 166 INDIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 175
TABLE 167 INDIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 176
TABLE 168 INDIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 176
TABLE 169 INDIA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 177
TABLE 170 MALAYSIA: NUMBER OF PATIENTS WITH BLEEDING DISORDERS: 2012–2016 178
TABLE 171 MALAYSIA: KEY MACROINDICATORS 178
TABLE 172 MALAYSIA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 178
TABLE 173 MALAYSIA: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 179
TABLE 174 MALAYSIA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD THOUSAND) 179
TABLE 175 MALAYSIA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 180
TABLE 176 MALAYSIA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 180
TABLE 177 ROAPAC: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 182
TABLE 178 ROAPAC: IMMUNOGLOBULINS MARKET, BY TYPE, 2016–2023 (USD MILLION) 182
TABLE 179 ROAPAC: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE,
2016–2023 (USD MILLION) 182
TABLE 180 ROAPAC: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 183
TABLE 181 ROAPAC: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 183
TABLE 182 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 184
TABLE 183 LATIN AMERICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2016–2023 (USD MILLION) 185
TABLE 184 LATIN AMERICA: COAGULATION FACTOR CONCENTRATES MARKET, BY TYPE, 2016–2023 (USD MILLION) 185
TABLE 185 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 186
TABLE 186 LATIN AMERICA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 186
TABLE 187 HEMOPHILIA PATIENTS IN THE MIDDLE EAST AND AFRICA: 2012–2016 187
TABLE 188 PER CAPITA CONSUMPTION OF FACTOR IX AND VIII (IU/TOTAL POPULATION:
2012–2016) 188
TABLE 189 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 188
TABLE 190 MIDDLE EAST & AFRICA: IMMUNOGLOBULINS MARKET, BY TYPE,
2016–2023 (USD MILLION) 189
TABLE 191 MIDDLE EAST & AFRICA: COAGULATION FACTOR CONCENTRATES MARKET,
BY TYPE, 2016–2023 (USD MILLION) 189
TABLE 192 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 190
TABLE 193 MIDDLE EAST & AFRICA: PLASMA FRACTIONATION MARKET, BY END USER,
2016–2023 (USD MILLION) 190
TABLE 194 EXPANSIONS, JANUARY 2014 TO DECEMBER 2017 194
TABLE 195 PRODUCT LAUNCHES, JANUARY 2014 TO DECEMBER 2017 195
TABLE 196 ACQUISITIONS, JANUARY 2014 TO DECEMBER 2017 195
TABLE 197 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS, JANUARY 2014 TO DECEMBER 2017 196


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 22
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 25
FIGURE 3 DATA TRIANGULATION METHODOLOGY 28
FIGURE 4 IMMUNOGLOBULINS SEGMENT TO DOMINATE THE PLASMA FRACTIONATION MARKET, BY PRODUCT, DURING 2018 TO 2023 30
FIGURE 5 NEUROLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 31
FIGURE 6 PLASMA FRACTIONATION MARKET, BY END USER, 2018 VS. 2023 (USD MILLION) 31
FIGURE 7 GEOGRAPHIC SNAPSHOT: PLASMA FRACTIONATION MARKET IN 2017 32
FIGURE 8 GROWING USE OF IMMUNOGLOBULINS IN VARIOUS THERAPEUTIC AREAS IS THE MAJOR FACTOR DRIVING MARKET GROWTH 34
FIGURE 9 ALBUMIN ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2017 35
FIGURE 10 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE PLASMA FRACTIONATION MARKET IN 2017 36
FIGURE 11 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 37
FIGURE 12 DEVELOPING COUNTRIES TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 37
FIGURE 13 COPD AND ASTHMA PREVALENCE, BY COUNTRY, 2015 41
FIGURE 14 GLOBAL PERCENTAGE OF DEATHS FROM RESPIRATORY DISEASES, 2008 TO 2030 42
FIGURE 15 PLASMA COLLECTION IN EUROPE, 2005–2013 42
FIGURE 16 SOURCE PLASMA COLLECTION IN THE US, 2007–2016 43
FIGURE 17 NUMBER OF HEMOPHILIA A AND HEMOPHILIA B PATIENTS WORLDWIDE,
2012–2016 45
FIGURE 18 INCREASING CONSOLIDATION AND RISING ADOPTION OF SCIG ARE THE LEADING INDUSTRY TRENDS 49
FIGURE 19 PLASMA FRACTIONATION MARKET IN CHINA VS. DEVELOPED COUNTRIES,
2018 VS 2023 53
FIGURE 20 PORTER’S FIVE FORCES ANALYSIS 57
FIGURE 21 IMMUNOGLOBULIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 66
FIGURE 22 ESTIMATED LIFETIME RISK OF ALZHEIMER’S DISEASE, BY AGE & SEX (2016) 67
FIGURE 23 PREVALENCE OF DIFFERENT BLEEDING DISORDERS, BY COUNTRY, 2016 75
FIGURE 24 COAGULATION FACTOR MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 77
FIGURE 25 MEAN PER CAPITA USAGE OF FACTOR VIII (2016) 78
FIGURE 26 MEAN PER CAPITA USAGE OF FACTOR IX (2016) 81
FIGURE 27 ALBUMIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 91
FIGURE 28 NEUROLOGY SEGMENT WILL CONTINUE TO DOMINATE THE PLASMA FRACTIONATION MARKET FROM 2018 TO 2023 96
FIGURE 29 NUMBER OF HEMOPHILIA PATIENTS IN MAJOR COUNTRIES, 2016 102
FIGURE 30 HOSPITALS & CLINICS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 113
FIGURE 31 PLASMA FRACTIONATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 121
FIGURE 32 NORTH AMERICA: PLASMA FRACTIONATION MARKET SNAPSHOT 123
FIGURE 33 NORTH AMERICA: PLASMA FRACTIONATION MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2017 126
FIGURE 34 PLASMA COLLECTION VOLUME IN THE US, 2007–2016 127
FIGURE 35 PLASMA COLLECTION CENTERS IN THE US, 2005–2016 128
FIGURE 36 US: PLASMA FRACTIONATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 131
FIGURE 37 EUROPE: PLASMA FRACTIONATION MARKET SNAPSHOT 137
FIGURE 38 EUROPE: PLASMA FRACTIONATION MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2017 140
FIGURE 39 HEMOPHILIA A & B PATIENTS IN GERMANY, 2013–2016 141
FIGURE 40 APAC: PLASMA FRACTIONATION MARKET SNAPSHOT 164
FIGURE 41 KEY STRATEGIES ADOPTED BY PLAYERS (JAN 2014–DECEMBER 2017) 191
FIGURE 42 GLOBAL PLASMA FRACTIONATION MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2017 192
FIGURE 43 CSL: COMPANY SNAPSHOT (2017) 197
FIGURE 44 GRIFOLS: COMPANY SNAPSHOT (2016) 201
FIGURE 45 SHIRE: COMPANY SNAPSHOT (2016) 205
FIGURE 46 OCTAPHARMA: COMPANY SNAPSHOT (2016) 209
FIGURE 47 KEDRION: COMPANY SNAPSHOT (2016) 211
FIGURE 48 LFB: COMPANY SNAPSHOT (2016) 215
FIGURE 49 BIOTEST: COMPANY SNAPSHOT (2016) 218
FIGURE 50 SANQUIN: COMPANY SNAPSHOT (2015) 221
FIGURE 51 CHINA BIOLOGIC PRODUCTS: COMPANY SNAPSHOT (2016) 223
FIGURE 52 JAPAN BLOOD PRODUCTS ORGANIZATION: COMPANY SNAPSHOT (2016) 228
FIGURE 53 GREEN CROSS CORPORATION: COMPANY SNAPSHOT (2016) 231


★調査レポート[血漿分画製剤の世界市場予測(~2023年):商品別(IVIG(静注免疫グロブリン)、アルブミン、第VIII因子、フォンヴィレブラント因子、PCC (プロトロンビン複合体製剤)、プロテアーゼ阻害剤)、用途別(免疫療法、血液疾患、救命治療、リウマチ)、エンドユーザー別(病院、クリニック、学術研究機関)] ( Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023 / MAM-PH-4477) 販売に関する免責事項
[血漿分画製剤の世界市場予測(~2023年):商品別(IVIG(静注免疫グロブリン)、アルブミン、第VIII因子、フォンヴィレブラント因子、PCC (プロトロンビン複合体製剤)、プロテアーゼ阻害剤)、用途別(免疫療法、血液疾患、救命治療、リウマチ)、エンドユーザー別(病院、クリニック、学術研究機関)] ( Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User (Hospital, Clinic, Academic Institute) - Global Forecast to 2023 / MAM-PH-4477) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆